Long-term Outcome of a Low-dose Intravesical Bacillus Calmette–Guerin Therapy for Carcinoma In Situ of the Bladder: Results After Six Successive Instillations of 40 mg BCG
Open Access
- 23 June 2005
- journal article
- research article
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 35 (7), 395-399
- https://doi.org/10.1093/jjco/hyi111
Abstract
Background: In Japan, bacillus Calmette–Guerin (BCG: Tokyo 172 strain) instillation is generally performed at a dose of 80 mg once weekly for eight consecutive weeks; however, many adverse effects including severe ones have been reported. We employed a dose of 40 mg once a week for six consecutive weeks in principle for carcinoma in situ (CIS) of the bladder, and retrospectively evaluated its effectiveness and safety. Methods: A total of 43 patients with CIS of the bladder were treated by this method and followed-up for a subsequent 12–79 months (median, 54 months). The patients consisted of 35 males and eight females aged 45–87 years (mean, 67.5 years). Intravesical BCG instillation at a dose of 40 mg was conducted once a week for six consecutive weeks. Results: A complete response (CR) was achieved in 84% of the patients, in whom the recurrence-free rate was 72.4% after 3 years and 61.9% after 5 years. The median CR duration was 37.5 months. Two patients underwent total cystectomy, but none died of bladder cancer. As adverse effects, bladder irritation symptoms were observed in 48.8%, pyuria in 46.5%, macroscopic hematuria in 18.6% and fever (>37.5°C) in 9.3%. There were no severe adverse effects requiring discontinuation of drug administration. Conclusion: Our present study corroborated both the effectiveness and safety of low-dose BCG therapy for CIS of the bladder. This therapy warrants further study by prospective randomized trials in the future.Keywords
This publication has 16 references indexed in Scilit:
- BACILLUS CALMETTE-GUERIN TOKYO172 SUBSTRAIN FOR SUPERFICIAL BLADDER CANCER: CHARACTERIZATION AND ANTITUMOR EFFECTJournal of Urology, 2005
- Adverse drug reactions of intravesical bacillus Calmette-Guerin instillation and risk factors of the development of adverse drug reactions in superficial cancer and carcinoma in situ of the bladderInternational Journal of Urology, 2005
- Sufficient prophylactic efficacy with minor adverse effects by intravesical instillation of low‐dose bacillus Calmette‐Guérin for superficial bladder cancer recurrenceInternational Journal of Urology, 2003
- LOW DOSE BACILLUS CALMETTE-GUERIN FOR CARCINOMA IN SITU OF THE BLADDER: LONG-TERM RESULTSJournal of Urology, 2000
- CURRENT METHODS OF ASSESSING AND TREATING CARCINOMA IN SITU OF THE BLADDER WITH OR WITHOUT INVOLVEMENT OF THE PROSTATIC URETHRAInternational Journal of Urology, 1995
- Intravesical Bacillus Calmette‐Guérin with the Danish Strain for Treatment of Carcinoma In situ of the BladderPublished by Wiley ,1993
- ABLATIVE AND PROPHYLACTIC EFFECTS OF BCG TOKYO 172 STRAIN FOR INTRAVESICAL TREATMENT IN PATIENTS WITH SUPERFICIAL BLADDER CANCER AND CARCINOMA IN SITU OF THE BLADDERThe Japanese Journal of Urology, 1992
- SERIOUS COMPLICATIONS OF INTRAVESICAL BACILLUS CALMETTE-GUERIN THERAPY IN PATIENTS WITH BLADDER CANCERThe Japanese Journal of Urology, 1991
- ANALYSES OF THE EFFECTS OF INTRAVESICAL BACILLUS CALMETTE-GUERIN (TOKYO 172 STRAIN) THERAPY FOR SUPERFICIAL BLADDER CANCERThe Japanese Journal of Urology, 1989